Skip to content

PT-141: Benefits & Research

Part of the PT-141 Complete Guide

Partner

Research Peptides

BioLongevity Labs15% Off
Shop Peptides at BioLongevity Labs

We may earn a commission if you purchase through this link, at no extra cost to you.

FDA-Approved for HSDD

PT-141 (Vyleesi) is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women — the first medication to target sexual desire through the central nervous system rather than vascular mechanisms. Phase 3 trials (RECONNECT) showed statistically significant improvements in desire scores and reductions in distress related to low desire.

Central Desire Enhancement

Unlike PDE5 inhibitors (Viagra, Cialis) that increase blood flow, PT-141 activates melanocortin-4 receptors (MC4R) in the hypothalamus, enhancing sexual desire and motivation through dopaminergic pathways. This central mechanism makes it effective for desire disorders where physical arousal is not the issue.

Research in Males

While FDA-approved only for premenopausal women, research shows PT-141 also enhances sexual desire and erectile function in men, including those who do not respond to PDE5 inhibitors. Studies demonstrated improved erection quality in men with erectile dysfunction through the central MC4R pathway.

Frequently Asked Questions

References

  1. Kingsberg SA, et al.. Bremelanotide for the treatment of hypoactive sexual desire disorder. Obstet Gynecol, 2019.
  2. Clayton AH, et al.. Bremelanotide for female sexual dysfunctions in premenopausal women. Women's Health, 2016.

Researching peptides? We did the hard part.

Get our free Peptide Starter Kit — the 5 most researched compounds, simplified into one actionable guide.

Related Guides

PI

Peptides Insider Editorial Team

Our content is reviewed for accuracy and grounded in peer-reviewed research where available. We do not provide medical advice. Always consult a qualified healthcare professional.